International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Uprising of Pyelonephritis in India: Are Antibiotics Enough?

Ribansuklang Marbaniang[1], Angbalaga Jessica[2], Apoorva Dev M[3], Dr. Pratyush Miglani[4]

[1,2]Rajiv Gandhi University
[3]East West College
[4]Sagar Hospital Jayanagar

Abstract:

Purpose: The efficacy of intravenous antibiotics used to treat febrile urinary tract infections (UTIs) is examined in this study, along with the risk factors for antibiotic resistance. It identified age, sex, and underlying UTIs as risk factors for antibiotic therapy failure. The severe UTI known as pyelonephritis, which causes inflammation in the kidney tissue, is a major public health concern in India. Finding the most effective course of action for this serious UTI is the goal of the study. This study examines the risk factors for antibiotic resistance and the effectiveness of intravenous antibiotics used to treat febrile urinary tract infections (UTIs). It identifies underlying urinary tract illness, age, and sex as risk variables for antibiotic treatment failure. Pyelonephritis, a severe UTI in India, is a significant public health concern due to kidney tissue inflammation. The study aims to determine the best treatment for this severe UTI. The study examined patient characteristics and antibiotic effectiveness, focusing on risk variables for antibiotic therapy length and treatment failure. Results showed that C-reactive protein was strongly associated with first antibiotic treatment failure. Pyelonephritis, a severe UTI in India, is a significant public health concern due to kidney tissue inflammation. The study aims to determine the best treatment for this severe UTI. The study examined patient characteristics and antibiotic effectiveness, focusing on risk variables for antibiotic therapy length and treatment failure. Results showed that C-reactive protein was strongly associated with first antibiotic treatment failure in complex acute pulmonary fibrosis (AP), while positive blood culture was correlated with uncomplicated AP. In uncomplicated AP, the length of antibiotic therapy was linked to diabetes mellitus or a positive blood culture.

Objectives: To ascertain whether using antibiotics to treat acute pyelonephritis and complex UTIs is safe and effective clinically

Methodology: Antibiotics, therapy, complex UTIs, and pyelonephritis were the main topics of the literature search. Acute pyelonephritis diagnosis or a complicated UTI requiring antibiotic use were prerequisites for eligibility. The data analysis method employed was descriptive because of variations in methods and treatments, and observational studies and clinical trials were included.

Results: This systematic study focused on pyelonephritis, antibiotics, treatment, urinary tract infection, and complicated UTI. It excluded case reports and reviews, included observational studies and clinical trials, and evaluated methodological excellence. A descriptive approach was chosen for data analysis due to differences in technique and interventions

Keywords: Antibiotics, Urinary tract infection, Pyelonephritis, Drug resistance

INTRODUCTION:

Acute pyelonephritis, one of the most prevalent kidney illnesses, is caused by a bacterial infection that inflames the kidneys. When a urinary tract infection (UTI) ascends from the bladder to the kidneys and their collecting systems, it can lead to complications including pyelonephritis. Frequency, urgency, burning when urinating, nausea, vomiting, fever, and flank discomfort are typical symptoms. Usually, flank discomfort and fever are the two most prevalent symptoms. Acute pyelonephritis is classified as either simple or complex. Individuals with immunocompromised conditions, hospital-acquired bacterial infections, kidney transplant recipients, pregnant patients, individuals with uncontrolled diabetes, urinary anatomical anomalies, and acute or chronic kidney failure are among those with complicated pyelonephritis. The difference between difficult and uncomplicated pyelonephritis must be made by the patient. The most common cause of pyelonephritis is the spread of bacteria from the bladder or urethra into the kidneys. Escherichia coli (E. coli) is the bacterium most often responsible for the infection. Factors that increase the risk of pyelonephritis include urinary tract obstructions, urinary catheterization, pregnancy, and conditions that weaken the immune system. Usually, the two most prevalent symptoms are flank discomfort and fever. There are two types of acute pyelonephritis: simple and complex. Patients with uncontrolled diabetes, kidney transplant recipients, anatomical abnormalities of the urine, acute or chronic kidney failure, immunocompromised individuals, and hospital-acquired bacterial infections are among the groups who are susceptible to complicated pyelonephritis. Differentiating between severe and simple pyelonephritis is crucial for patient care and outcome. For various patient categories, different treatment suggestions are made, ranging from outpatient therapy to inpatient care.(4–8) Previous research has demonstrated that controlling acute pyelonephritis and lowering hospital admissions are possible with observational treatment.(9,10) With the recognized risks of septic shock, multiple organ failure, and death in extreme situations, choosing the right unit for a patient can optimize treatment, lower morbidity and mortality, and make better use of the hospital's limited resources. One or both kidneys may be impacted by a urinary tract infection (UTI) called pyelonephritis. Escherichia coli (E. coli), which typically lives in the digestive system but can enter the urinary tract and cause infection, is the most frequent bacteria that cause pyelonephritis. Pyelonephritis can also be brought on by other bacteria, including Enterococcus, Proteus, and Klebsiella. Pyelonephritis is determined by a physical examination, a combination of symptoms, and diagnostic testing like Urinalysis to determine if the urine contains bacteria, red blood cells, or white blood cells. Urine culture to pinpoint the precise bacteria causing the illness and ascertain the best course of treatment.

Blood tests to determine the extent of the illness and look for indicators of a systemic infection, such as a complete blood count (CBC) and blood cultures. Imaging studies to see the kidneys and urinary system and find any anomalies, procedures like ultrasound, CT scan, or MRI may be carried out. Antibiotics are usually used to treat pyelonephritis in order to get rid of the bacterial infection. The severity of the infection, the suspected or confirmed bacteria, and any underlying medical issues all influence the use of antibiotics. Hospitalization may be required in severe instances or cases with complications in order to get supportive care and intravenous antibiotics. Pyelonephritis can result in severe consequences like the following if it is not treated or is not treated well enough. Adults with acute pyelonephritis have been treated with a variety of antibiotic classes. These include carbapenems, the polymyxin group of antibiotics, trimethoprim-sulfamethoxazole, nitrofurantoin, quinolones, aminoglycosides, cephalosporins, and

extended penicillin (amoxicillin-clavulanic acid, piperacillin-tazobactam) (Herness 2020). Some are parenteral only, some oral, and others oral and parenteral, depending on the patient's clinical stability and antibiotic sensitivity. When oral formulations of sensitive antibiotics are not available, blockage, severe pyelonephritis, or underlying debilitating diseases are present, parenteral antibiotics must be used at least initially. Treatment lasts anywhere from five to fourteen days, although in cases of kidney abscesses or emphysematous pyelonephritis, it is frequently prolonged to six weeks. Based on the level of antibiotic resistance in the area, an empirical selection of antibiotics should be made initially. The outcomes of the urine culture should subsequently be used to modify the antibiotic treatment. The most common cause of simple instances of acute pyelonephritis is E. coli, which may be treated for 14 days with TMP-SMX or oral cephalosporins. Intravenous (IV) antibiotic therapy is necessary for complex cases of acute pyelonephritis until clinical improvements occur. Fluoroquinolones, cefepime, meropenem, and piperacillin-tazobactam are a few examples of IV antibiotics. Vancomycin can be used for people with penicillin allergy. Follow-up for non-admitted patients should occur within a day or two in order to assess symptom remission. Results from a urine culture should only be collected for patients who had a difficult course. Eight evaluable studies comparing ≤7 with >7 days of therapy for pyelonephritis were discovered using a meta-analysis. Whether or not fluoroquinolones had been used, the meta-analysis concluded that there were no differences in microbiological or clinical failure between the short and long treatment groups. Patients with urogenital anomalies exhibited higher microbiological failure (but equal clinical failure) at the end of follow-up than those with normal anatomy, suggesting longer treatment courses for pyelonephritis accompanied by abscess or stones. The percentage of patients with bacteraemia varied from 3% to 29% in this meta-analysis (73). Comparing a median of 4.5 days of aminoglycoside therapy with 5 days of non-aminoglycoside-based therapy for adults with pyelonephritis, recent research (65% females) revealed comparable results (77). Nevertheless, there are drawbacks to the antibiotics that are now advised, including drug side effects, the existence of germs that are resistant to antibiotics, and treatment noncompliance. In order to enhance the prognosis and result of the patients, other antibiotics need to be taken into account. When treating acute pyelonephritis, other medicines—such as new drugs or combination therapy—might be more beneficial than the antibiotics recommended by the recommendations. Based on recent research, the review's objective was to examine the clinical effectiveness and safety of antibiotics in the management of acute pyelonephritis.

MATERIALS AND METHODS:

Every year, there are over 250,000 instances of acute pyelonephritis, which lead to over 100,000 hospital admissions. Escherichia coli infection is the most frequent etiologic cause. For urinary tract infections, the leukocyte esterase test and the nitrite test combined have a sensitivity of 75 to 84 percent and a specificity of 82 to 98 percent (assuming both tests are positive). Ninety percent of patients with acute pyelonephritis have positive urine cultures, which is why cultures should be taken prior to starting antibiotic treatment. Blood cultures should only be used on patients who are immunocompromised, have an unclear diagnosis, or are suspected of having hematogenous infections. For most patients with minor infections, outpatient oral antibiotic treatment with a fluoroquinolone is beneficial. Extended-spectrum penicillin, amoxicillin-clavulanate potassium, cephalosporins, and trimethoprim-sulfamethoxazole are other useful substitutes. Complex infections, sepsis, recurrent vomiting, ineffective outpatient therapy, or advanced age are among the conditions that call for inpatient care. Intravenous therapy with a fluoroquinolone, aminoglycoside with or without ampicillin, or a third-generation cephalosporin is advised for hospitalized patients.

Therapy sessions often last seven to fourteen days. It is recommended to do another urine culture 1-2 weeks following the conclusion of antibiotic medication. Immunosuppressive conditions, underlying anatomical or functional defects, or resistant organisms can all contribute to treatment failure. If there is no reaction, further blood and urine cultures as well as maybe imaging tests should be performed. It might be necessary to switch to a different antibiotic or have surgery.

STATISTICAL ANALYSIS:

We prospectively collected all patients hospitalized at our tertiary care hospital from March 2014 to June 2016 with a diagnosis of pyelonephritis (PN) aged more than 14 years. SAS, SPSS 15.0 (SPSS, Inc., Chicago, IL), Stata 10.1, MedCalc 9.0.1 Systat 12.0 (Systat Software, San Jose, CA), and R environment version 2.11.1 (R Foundation for Statistical Computing in Vienna, Austria) were used for the analysis of the data, and Microsoft Word and Excel have been used to. Antibiotics are the mainstay for treating acute pyelonephritis, although there are still differences in the best medication, how long it should last, and how to administer it (Gupta 2011). Berti (2018) conducted a systematic study that compared the usage of long-course vs short-course antibiotics for pyelonephritis. Nevertheless, they did not concentrate on pyelonephritis caused by drug-resistant organisms or on pyelonephritis that was complex.

Reducing the length of time individuals with acute pyelonephritis get antibiotics would safely lead to shorter hospital stays, avoidable prolonged use of antibiotics, and maybe lower costs, side effects, and antimicrobial resistance. Given the global context of growing antibiotic resistance.

If acute pyelonephritis is not well treated, it can cause renal damage in the form of AKI and CKD. Thus, it is essential to understand

RESULTS:

Antibiotics are the mainstay for treating acute pyelonephritis, although there are still differences in the best medication, how long it should last, and how to administer it (Gupta 2011). Berti (2018) conducted a systematic study that compared the usage of long-course vs short-course antibiotics for pyelonephritis. Nevertheless, they did not concentrate on pyelonephritis caused by drug-resistant organisms or on pyelonephritis that was complex.

Reducing the length of time individuals with acute pyelonephritis get antibiotics would safely lead to shorter hospital stays, avoidable prolonged use of antibiotics, and maybe lower costs, side effects, and antimicrobial resistance. Given the global context of growing antibiotic resistance, this is particularly crucial.

If acute pyelonephritis is not well treated, it can cause renal damage in the form of AKI and CKD. Therefore, it is crucial to understand the best antimicrobial therapy to avoid these crippling long-term effects.

The majority of guidelines suggest parenteral antibiotics for patients with severe pyelonephritis, underlying disabling diseases, or blockage; oral antibiotics are recommended for those who are clinically stable. Unfortunately, many nations lack sensitive oral antibiotics due to the rise of antimicrobial resistance.

Given that pricey antibiotics and bed fees account for a significant portion of hospital expenditures, the cost of therapy might be high. For acute pyelonephritis, current guidelines suggest a duration of five to fourteen days. The total cost to the health system might be lower if antibiotics with shorter half-lives are just as effective as those with longer half-lives. Previous evaluations have not included documentation for

them.

Outcomes of the study:

DISCUSSIONS:

Acute pyelonephritis presents a diagnostic challenge due to its diverse clinical manifestations and potential overlap with other conditions such as lower urinary tract infections. The text emphasizes the importance of a thorough diagnostic approach, including urinalysis, urine culture, blood tests, and imaging studies, to accurately diagnose and differentiate pyelonephritis from other conditions. The choice of antibiotics for treating acute pyelonephritis depends on several factors, including the severity of infection, suspected pathogens, and local antibiotic resistance patterns. The text suggests a duration of five to fourteen days for antibiotic treatment, with adjustments based on clinical response and urine culture results. However, there is ongoing debate and research regarding the optimal duration of antibiotic therapy, especially in light of rising antimicrobial resistance and the potential for adverse effects associated with prolonged antibiotic use. Managing complex cases requires a multidisciplinary approach and may necessitate hospitalization for close monitoring and intravenous antibiotic therapy. The emergence of antimicrobial resistance poses significant challenges in the treatment of acute pyelonephritis. The text underscores the importance of considering local antibiotic resistance patterns and tailoring antibiotic therapy accordingly. However, there is a need for further research to evaluate the clinical effectiveness and safety of alternative antibiotic regimens, particularly in the context of drug-resistant organisms and complex cases of pyelonephritis. The text suggests that reducing the duration of antibiotic therapy could lead to shorter hospital stays, lower costs, and decreased antimicrobial resistance. However, implementing such strategies requires careful consideration of patient outcomes, treatment efficacy, and healthcare resource utilization.

PURPOSE OF THE STUDY:

The study aims to evaluate the clinical effectiveness and safety of various antibiotics in the management of acute pyelonephritis. This includes assessing the efficacy of different antibiotic classes, treatment durations, and administration routes in improving patient outcomes and minimizing adverse effects. By comparing short-course versus long-course antibiotic regimens, the research aims to determine whether shorter treatment durations can achieve comparable clinical outcomes while minimizing hospital stays, antibiotic exposure, and healthcare costs. the study may investigate the prevalence of drug-resistant organisms in acute pyelonephritis and assess strategies for mitigating antimicrobial resistance. This includes evaluating antibiotic selection practices, resistance patterns, and the impact of local resistance on treatment outcomes. The study may analyse healthcare resource utilization and costs associated with the management of acute pyelonephritis. By examining factors such as hospital admissions, antibiotic expenditures, and length of stay, the research aims to identify opportunities for optimizing resource allocation and reducing healthcare expenditures.

CONCLUSION:

Several new antibiotics and combination therapies have demonstrated effectiveness in treating complex urinary tract infections (UTIs) and pyelonephritis. Clinical evidence suggests that shorter treatment durations and reduced antibiotic consumption are effective strategies, which may help mitigate the development of multidrug-resistant bacteria. Ceftazidime-avibactam, piperacillin-tazobactam, and tazobactam-ceftolozane can serve as alternatives to carbapenems for treating ESBL-producing E. coli.

Additionally, meropenem-vaborbactam, piperacillin-tazobactam, and tazobactam-ceftolozane exhibit high cure rates in the management of complex UTIs and pyelonephritis. Hence, novel antibiotics and combination therapy options should be considered when facing resistance to standard antibiotics. In forthcoming trials, it is imperative to adopt standardized diagnostic criteria and outcome measures for direct comparisons. Furthermore, future research should aim to delineate the patient populations that may benefit from specific antibiotics, thus improving clinical outcomes and prognosis.

REFERENCE:

1. Yasufuku, T., Shigemura, K., Arakawa, S., Fujisawa, M., Shigemura, K., & Yamashita, M. (2011). Selection of first-line I.V. antibiotics for acute pyelonephritis in patients requiring emergency hospital admission. Journal of Infection and Chemotherapy, 17(2), 231–237.
2. AK P. Acute emphysematous pyelonephritis in adults. Cell & Cellular Life Sciences Journal. 2018;3(2). doi:10.23880/cclsj-16000129.
3. Urinary tract infection (UTI, cystitis: Acute). The APRN and PA's Complete Guide to Prescribing Drug Therapy. 2019 Apr; doi:10.1891/9780826179340.0406.
4. AK P. Acute emphysematous pyelonephritis in adults. Cell & Cellular Life Sciences Journal. 2018;3(2). doi:10.23880/cclsj-16000129.
5. Pyelonephritis: Acute. The APRN and PA's Complete Guide to Prescribing Drug Therapy. 2019 Apr; doi:10.1891/9780826179340.0335.
6. Lee HN, Yoon H. Management of antibiotic-resistant acute pyelonephritis. Urogenital Tract Infection. 2017;12(3):95. doi:10.14777/uti.2017.12.3.95.
7. Ong LT. Antibiotics for complicated urinary tract infection and Acute Pyelonephritis: A systematic review. World Journal of Clinical Infectious Diseases. 2020 Sept 18;10(3):33–41. doi:10.5495/wjcid.v10.i3.33.
8. Jansåker F, Li X, Vik I, Frimodt-Møller N, Knudsen JD, Sundquist K. The risk of pyelonephritis following uncomplicated cystitis: A Nationwide Primary Healthcare Study. Antibiotics. 2022 Nov 24;11(12):1695. doi:10.3390/antibiotics11121695.
9. Nabi T, Rafiq N, Rasool S, Sheikh R. A prospective study of emphysematous pyelonephritis in patients with type 2 diabetes. Indian Journal of Nephrology. 2021;31(6):536. doi:10.4103/ijn.ijn_411_19.
10. Richard G, Klimberg I, Fowler C, Callery-D'Amico S, Kim S. Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. Urology. 1998 Jul;52(1):51–5. doi:10.1016/s0090-4295(98)00160-5.
11. Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, et al. Ceftolozane/Tazobactam: A novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2013 Dec 19;74(1):31–51. doi:10.1007/s40265-013-0168-2.
12. Yasufuku T, Shigemura K, Arakawa S, Fujisawa M, Shigemura K, Yamashita M, Selection of first line antibiotics for acute pyelonephritis in patients requiring emergency hospital admission. Journal of Infection and Chemotherapy. 2011;17(2):231–7. doi:10.1007/s10156-010-0116-y.
13. S37.5 duration of antibiotic treatment for acute "non complicated" Pyelonephritis: A systematic approach. International Journal of Antimicrobial Agents. 2005 Jan;26. doi:10.1016/s0924-8579(05)80152-9